A large prospective survey of adults planning to take psilocybin outside clinical settings found that, on average, participants reported lasting reductions in anxiety, depression, and alcohol misuse, along with improvements in cognitive flexibility, emotion regulation, spiritual wellbeing, and extraversion, and decreases in neuroticism and burnout after use. However, a minority reported persisting negative effects: 11% at 2–4 weeks and 7% at 2–3 months after use, including mood fluctuations and depressive symptoms. The study included 2,833 respondents at baseline, 1,182 at 2–4 weeks, and 657 at 2–3 months post-use. Participants were primarily college-educated White men in the United States, mean age 40, who used dried psilocybin mushrooms (mean dose 3.1 grams) for self-exploration.
Classic psychedelics that activate the serotonin 2A receptor are being explored as potential treatments for mental health conditions, with evidence suggesting they can produce lasting reductions in anxiety and depression after a single dose. Acute subjective effects appear important for therapeutic benefits. Animal studies indicate these compounds may also influence learning and memory, with relevance for Alzheimer's disease and related dementias. Proposed biological mechanisms include enhanced neuroplasticity, anti-inflammatory effects, and altered brain connectivity. Human research suggests high-dose psychedelics might help treat depressed mood and anxiety in early-stage Alzheimer's. Preclinical data hint at potential to slow brain atrophy, enhance cognition, and slow disease progression, though further research is needed.